Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

es not support marketing approval, whether regulatory authorities will approve JUNOVAN within the time frame expected by the Company or at all, and whether the Company will be able to manufacture JUNOVAN even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2006 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

    CONTACT:

    Bob De Vaere

    IDM Pharma, Inc.

    Chief Financial Officer

    Office: 949-470-6447

CONTACT: Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc.,+1-949-470-6447

Web site: http://www.idm-pharma.com/

Ticker Symbol: (NASDAQ-NMS:IDMI),(NYSE:SNY)

'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... N.J., Feb. 3, 2011 BioNeutral Group, Inc. (OTC ... science technology-based company, today announced the formation of BioNeutral ... Inc., and the appointment of Frank Battafarano as the ... BioNeutral Services will market and distribute a ...
... 2011 A VANIR Pharmaceuticals, Inc. ... the three months ended December 31, 2010. For the ... $12.1 million, or $0.11 loss per share, compared with a net ... same period in fiscal 2010. Net revenues consisting primarily of royalty ...
Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 2AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 4AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 5AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 6
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
(Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
Breaking Medicine News(10 mins):Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
... and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals,today ... healthy subjects in,a Phase I study of AFN-1252, ... class of fatty acid biosyntheis inhibitors. The study ... of a single,escalating oral dose. Affinium believes that ...
... , The doctoral thesis of Isaac Manuel lvarez Ruiz ... Signal Theory, Telematics, and Communication , and Department of Surgery ... and directed by Professors ngel de la Torre Vega ... work includes improving the acquisition of Compound Action Potential records, carrying ...
... of Health,Dr. Calvin B. Johnson today met with ... discuss Governor Edward G. Rendell,s plan to,provide access ... uninsured,adults through his "Cover All Pennsylvanians" proposal., ... prevent disease,successfully manage chronic diseases such as diabetes ...
... fleet golf car and the role of MES, ... execution systems (MES) for the integrated enterprise,announced today that ... E-Z-GO Fleet Golf Car: Integrating Manufacturing,Execution with New Product ... March 6, 2008 at 2:00 p.m. EST., During ...
... retained 1 year after therapy , , TUESDAY, March 4 ... shows promise in adults, say American and Chinese researchers ... , Lazy eye, also known as amblyopia, has been ... condition, especially those in developing countries, are diagnosed too ...
... Promotes National Kidney Month Programs to,Combat Spread of ... WASHINGTON, March 4 DaVita Patient Citizens,(DPC) ... more than 22,000,dialysis and pre-dialysis patients and family ... all dialysis patients through education and,advocacy -- enthusiastically ...
Cached Medicine News:Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 3Health News:Health Secretary's Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 3Health News:New Treatment for 'Lazy Eye' Shows Promise 2Health News:Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans 2
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
Medicine Products: